Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), a Delaware corporation and emerging growth company, filed this Form 8-K on June 24, 2025. The filing reports the entry into a Material Definitive Agreement and the unregistered sale of equity securities.
Key Financial Metrics and Transaction Details
The filing details a Stock Purchase Agreement (SPA) with Prevail Partners, LLC ("Prevail") rather than standard periodic financial results.
- Total Transaction Value: $587,905 in aggregate consideration.
- Payment Structure:
- Upfront Payment: $58,800.3333 worth of shares.
- Tranche Payments: 36 equal payments of $14,697.333 each.
- Pricing Mechanism: Shares are priced at 120% of the 30-day volume-weighted average price (VWAP) on the NYSE American, subject to a Minimum Share Price of $1.74.
- Maximum Dilution: At the minimum price, up to 337,876 shares may be issued. A 19.99% blocker prevents issuance exceeding 19.99% of outstanding shares.
- Use of Proceeds: Funds will pay for technologies and services from Prevail Infoworks (an affiliate) for a Phase 3 study of THIO sequenced with cemiplimab (LIBTAYO) for advanced/metastatic non-small cell lung cancer.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
This filing represents a material change in the company's capital structure and operational funding. The company has entered into a financing arrangement to fund a specific clinical trial (Phase 3 study) via the issuance of unregistered common stock.
Guidance, Outlook, and Risks
Outlook: The transaction supports the execution of a multicenter, open-label, randomized Phase 3 study evaluating THIO as a third-line treatment.
Risks and Contingencies:
- Dilution Risk: Future share issuances depend on market price (VWAP), though capped by the 19.99% blocker.
- Related Party Transaction: Proceeds are used to pay an affiliate (Prevail Infoworks) under a Master Service and Technology Agreement dated September 24, 2024.
- Regulatory Status: Shares are issued pursuant to exemptions under Section 4(a)(2) and/or 3(a)(9) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the current outstanding share count to calculate the exact dilution impact of the 19.99% blocker.
- Review the Master Service and Technology Agreement (MSTA) dated September 24, 2024, to understand the scope of services provided by the affiliate.
- Monitor the 30-day VWAP to estimate the actual number of shares to be issued in future tranches.
- Confirm the status of the Phase 3 study for THIO sequenced with cemiplimab in non-small cell lung cancer.